← All trials
NCT05857046
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2023
- Primary completion
- Dec 15, 2024
- Completion date
- May 14, 2025
- First posted
- May 12, 2023
- Last posted
- May 12, 2023
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of MexicoLead sponsor
- Government of MexicoReponsible party - principal investigator
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del EstadoCollaborator
- Instituto Mexicano del Seguro SocialCollaborator
- Instituto Mexicano del Seguro SocialOverall official - principal investigator
- Government of MexicoSponsor investigator
- Instituto Mexicano del Seguro SocialOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.